Skip to main content

Table 1 Overview of the research questions and setup of the subsequent studies

From: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model

Research question (rat strain) Study Groups Number 177Lu-TATE (MBq) RAD001 (dose, period)
(A) Potential synergistic effect of RAD001 in combination with 177Lu-TATE (LEW/HanHsd) 1 Control 7 - Placebo
RAD only 6 - 5.0 mg/kg, 4.5 w
177Lu-TATE low dose 7 125 Placebo
177Lu-TATE high dose 7 275 Placebo
RAD + 177Lu-TATE low dose 7 125 5.0 mg/kg, 4.5 w
RAD + 177Lu-TATE high dose 7 275 5.0 mg/kg, 4.5 w
(B) Prolonged follow-up of potential development of distant metastasis (LEW/HanHsd) 2 Control 8 - Placebo
Low-dose RAD 8 - 2.5 mg/kg, 4.5 w
High-dose RAD 8 - 5.0 mg/kg, 4.5 w
177Lu-TATE 7 125 Placebo
177Lu-TATE + low-dose RAD 8 125 2.5 mg/kg, 4.5 w
177Lu-TATE + high-dose RAD 7 125 5.0 mg/kg, 4.5 w
(C) Influence of RAD001 on tumor uptake of 177Lu-DOTATATE (LEW/HanHsd) 1 + 2 177Lu-TATE 21 125 or 275 Placebo
RAD + 177Lu-TATE 29 125 or 275 2.5 mg/kg or 5.0 mg/kg, 4.5 w
(D) Effects of prolonged RAD001 treatment (LEW/SsNHsd) 3 Control 8 - Placebo
RAD 8 - 5.0 mg/kg, 4.5 w
177Lu-TATE + RAD 8 125 5.0 mg/kg, 4.5 w
RAD prolonged treatment 8 - 5.0 mg/kg, 12 w
177Lu-TATE + RAD prolonged treatment 8 125 5.0 mg/kg, 12 w
(E) Effects of PRRT on growth of metastases (LEW/SsNHsd) 3 High-dose 177Lu-TATE after diagnosis of metastases 7 400 -
  1. 177Lu-TATE, 177Lu-DOTA0,Tyr3-octreotate; RAD, RAD001; PRRT, peptide receptor radionuclide therapy; w, weeks.